Some holders running for the exit. I think the reaction on the Nasdaq could be interesting tonight.
* Orphan drug in US and EU markets
* Blockbuster market potential
* Successful P1 trial building on the impressive preclinical studies
* EV almost nil taking into account cash on hand
* Likely to attract a lot of interest from prospective partners
There is a lot to like at under 2.5c
I'm in.
Ann: European Orphan Designation granted for PBT434 for MSA, page-5
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
-0.001(25.0%) |
Mkt cap ! $15.96M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.3¢ | $4.734K | 1.341M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 49 | 30295639 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 129917446 | 34 |
View Market Depth
| Last trade - 15.44pm 15/10/2024 (20 minute delay) ? |
| ATH (ASX) Chart |